RTS, S, a subunit malaria vaccine candidate composed of the CSP repeats and the TSR domain fused to the hepatitis B surface antigen has shown promise in Phase III clinical trials [7], [8], validating the CSP repeats as a vaccine target. The gene discussed is DNAJC5; the disease is malaria.